Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Vanda Pharmaceuticals | 310.98 Mn | 108.67 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.63% |
| Dec 31, 2025 | -525.00% |
| Sep 30, 2025 | 16.91% |
| Jun 30, 2025 | 7.82% |
| Mar 31, 2025 | -504.88% |
| Dec 31, 2024 | 8.76% |
| Sep 30, 2024 | -18.28% |
| Jun 30, 2024 | -8.97% |
| Mar 31, 2024 | -73.40% |
| Dec 31, 2023 | -1,845.26% |
| Sep 30, 2023 | -90.82% |
| Jun 30, 2023 | -53.78% |
| Mar 31, 2023 | -52.95% |
| Dec 31, 2022 | 110.40% |
| Sep 30, 2022 | 25.91% |
| Jun 30, 2022 | 140.07% |
| Mar 31, 2022 | -191.33% |
| Dec 31, 2021 | -8.34% |
| Sep 30, 2021 | -20.00% |
| Jun 30, 2021 | 11.60% |